Back to Operative Surgery
Oncology

Curettage, Local Adjuvant & Reconstruction (GCT and benign-aggressive bone lesions)

Surgical technique guide for intralesional extended curettage of benign-aggressive bone lesions - cortical window, high-speed burr, local adjuvants (phenol, cryotherapy, PMMA), cavity reconstruction, and giant cell tumour specifics including denosumab

Core Procedure
advanced
By OrthoVellum Medical Education Team

Reviewed by OrthoVellum Editorial Team

Editorial maintenance, source checking, and correction workflow • Published by OrthoVellum Medical Education Team

Editorial boardMethodologyReview policyReport a correction
High-yield overview

Intralesional extended curettage for giant cell tumour and benign-aggressive bone lesions | advanced

Surgical Imaging

Extended curettage with high-speed burr
Extended intralesional curettage: a generous cortical window lets the whole cavity be curetted, then a high-speed burr extends the margins — a small window is the commonest cause of recurrence.Credit: AI-generated medical image · OrthoVellum
Local adjuvant therapy to the curetted cavity
Local adjuvants (here cryotherapy; also phenol, hydrogen peroxide, argon beam or the heat of cement) destroy residual tumour cells at the cavity wall after curettage.Credit: AI-generated medical image · OrthoVellum
PMMA cement reconstruction of a bone cavity
Cavity reconstruction with PMMA cement over a subchondral bone-graft layer: immediate stability, an exothermic adjuvant effect, and a clear cement-bone interface for recurrence surveillance.Credit: AI-generated medical image · OrthoVellum

Critical Principles and Exam Traps

The Window Determines Recurrence

The trap: Making a window the size of the radiographic lytic area, or a keyhole through intact cortex. Residual tumour hides in locules and behind septa you cannot see.

The fix: Create a cortical window that exposes the WHOLE cavity from end to end. The single most important technical factor in reducing recurrence is direct visualisation of every part of the cavity.

Curettage Is Not Enough Alone

The trap: Mechanical curettage alone leaves microscopic tumour in the bony interstices and gives recurrence rates of 25-50% in giant cell tumour.

The fix: ALWAYS follow curettage with a high-speed burr to extend the margin, then a local adjuvant (chemical, thermal, or cement exotherm). Extended curettage lowers GCT recurrence to roughly 10-20%.

Phenol and the Neurovascular Bundle

Risk: Phenol is a caustic protein coagulant. Spillage onto skin, the neurovascular bundle, or the joint causes chemical burns, nerve injury, and chondrolysis.

The fix: Protect soft tissues with swabs and a sealed field, apply phenol with a cotton-tipped applicator under controlled conditions, then neutralise with absolute alcohol. Never use phenol where the cavity communicates with the joint.

Cryotherapy and Fracture / Skin

Risk: Liquid nitrogen freezes a 1-2 cm margin of bone but weakens it — postoperative fracture risk is real. Spillage causes skin necrosis; overflow near nerve causes neurapraxia.

The fix: Protect skin (warm saline irrigation, gutter of gauze), augment the construct (cement and/or fixation), and protect weight-bearing. Modern closed-system probes reduce spillage versus pour techniques.

Cement vs Graft and Surveillance

The trade-off: PMMA gives immediate stability, an adjuvant exotherm, and a sharp radiographic interface that makes early recurrence easy to detect. Bone graft is biological but OBSCURES the cavity radiographically and has no adjuvant effect.

Implication: For benign-aggressive lesions where recurrence surveillance matters (GCT), cement is often preferred. Graft favoured in children, smaller benign cysts, and when biological restoration is the priority.

Don't Curette a Chondrosarcoma

The trap: Treating a pain-causing, endosteally-scalloped cartilage lesion as a benign enchondroma. Intralesional surgery of a true (intermediate/high-grade) chondrosarcoma seeds the field and compromises cure.

The fix: Confirm low grade before curettage. Only low-grade central (atypical cartilaginous / grade 1) lesions are curetted in selected centres; deep endosteal scalloping, pain, and growth point to formal resection.

Mnemonic

C.U.R.E.T.T.ECURETTE — The Extended Curettage Sequence

Mnemonic

G.I.A.N.TGIANT — Giant Cell Tumour of Bone Essentials

What Gets Curetted — and What Does Not

Intralesional extended curettage is the workhorse joint-preserving operation for benign-aggressive and selected benign-latent/active bone lesions. The principle is the same across diagnoses: remove the lesion, extend the margin, kill residual cells, and reconstruct — preserving the adjacent joint and accepting a low local recurrence rate in exchange for limb and joint function.

Lesions Amenable to Extended Curettage

  • Giant cell tumour of bone (GCT) — the exemplar benign-aggressive lesion; Campanacci I-II and many III
  • Aneurysmal bone cyst (ABC) — primary or secondary; curettage with adjuvant, often with grafting
  • Chondroblastoma — epiphyseal lesion of the immature skeleton; meticulous curettage to protect the physis and joint
  • Simple (unicameral) bone cyst — curettage/decompression and grafting when injection/aspiration fails or fracture risk is high
  • Enchondroma (symptomatic / fracture risk) — curettage and graft; distinguish from low-grade chondrosarcoma
  • Low-grade central chondrosarcoma (atypical cartilaginous tumour, grade 1) — extended intralesional curettage with adjuvant in selected centres for appendicular lesions
  • Chondromyxoid fibroma, fibrous dysplasia (focal), eosinophilic granuloma — selected symptomatic/structural cases

Indications

  • Symptomatic or structurally threatening benign-aggressive lesion with adequate residual bone stock for reconstruction
  • Joint-sparing intent — subchondral bone and articular surface salvageable
  • Histologically confirmed benign or benign-aggressive diagnosis (biopsy first if any doubt)

Contraindications to Intralesional Surgery

Absolute:

  • Confirmed intermediate- or high-grade malignancy (e.g. grade 2-3 chondrosarcoma, osteosarcoma) — requires wide en bloc resection
  • Extensive joint destruction or pathological fracture with intra-articular tumour where reconstruction cannot restore a functional joint

Relative:

  • Massive cortical breach / soft-tissue mass (favours resection)
  • Multiply recurrent GCT after adequate curettage (consider resection)
  • Lesion abutting articular cartilage so closely that adjuvant would damage the joint

Joint-Preserving Curettage vs En Bloc Resection

En bloc (wide) resection cures the lesion with a margin of normal tissue but sacrifices the joint and requires reconstruction (endoprosthesis, osteoarticular allograft, arthrodesis). It is reserved for extensive bony/articular destruction, large soft-tissue extension, multiply recurrent disease, or malignancy. For the majority of GCT and benign-aggressive lesions, extended curettage achieves comparable oncological control with far better function.

Lesions and the Curettage Approach


Clinical Decision Scenarios

Use these scenarios to practise clinical reasoning and management decisions

CLINICAL SCENARIOAdvanced

CLINICAL PROMPT

"A 32-year-old presents with knee pain. Radiographs show an eccentric, lytic, expansile lesion in the distal femur extending to the subchondral bone, with a thinned but intact cortex (Campanacci grade II). Biopsy confirms giant cell tumour of bone. How do you manage this?"

PRACTICAL APPROACH
This is a classic appendicular benign-aggressive giant cell tumour with a salvageable joint, so my goal is a joint-preserving intralesional EXTENDED curettage rather than resection. I would aim to control the tumour while preserving the knee, accepting a recurrence rate of around 10-20% in exchange for function. **Staging and planning**: I would have an MRI to define marrow and soft-tissue extent, a CT to assess cortical integrity and fracture risk, and a staging CT chest because GCT can produce benign pulmonary metastases in 3-5%. I confirm the histology and grade before definitive surgery. **Operative plan — extended curettage**: I plan an approach that includes the biopsy tract and protects future resection planes. I pack off and protect the soft tissues, then make a LARGE cortical window exposing the ENTIRE cavity — an inadequate window leaving hidden locules is the single commonest cause of recurrence. I perform thorough mechanical curettage of all locules and septa with a full range of curettes, then extend the margin with a high-speed burr into macroscopically normal bone. I then apply a local adjuvant — for example phenol with alcohol neutralisation, hydrogen peroxide, or cryotherapy — in a sealed, protected field, and pulsed-lavage the cavity. **Reconstruction**: For a peri-articular GCT around the knee I favour PMMA cement — it gives immediate stability, the polymerisation exotherm is an additional thermal adjuvant, and the sharp cement-bone interface makes radiographic surveillance for recurrence straightforward. I lay a thin layer of subchondral cancellous graft under the cement to protect the articular cartilage from the exotherm and stiffness. If the construct is structurally compromised I add a buttress plate. **Follow-up**: Regular surveillance radiographs of the knee (watching the cement-bone interface) and chest imaging, as most recurrences appear within 2 years. **Counselling**: I would discuss the 10-20% recurrence risk, the rare risks of malignant transformation and benign lung metastases, and that recurrence is usually treatable with repeat extended curettage.
CLINICAL SCENARIOAdvanced

CLINICAL PROMPT

"During curettage of a giant cell tumour you are planning to use a chemical adjuvant. Talk me through the principles of local adjuvants — what options exist, and what are the specific hazards of each?"

PRACTICAL APPROACH
A local adjuvant treats the microscopic residual tumour in the bony interstices that mechanical curettage and burring cannot physically remove. It converts an intralesional excision into a more effective local control, lowering recurrence toward resection-level rates while preserving the joint. Adjuvants are chemical, thermal, or mechanical, and many surgeons combine one with cement, whose exotherm adds a further thermal kill. **Chemical**: Phenol (5%) is a protein coagulant that I apply on cotton-tipped applicators in a sealed, soft-tissue-protected field and then neutralise with absolute alcohol. Its hazard is that it is caustic — spillage burns skin, nerve, and cartilage, so I never use it where the cavity communicates with the joint or near an unprotected nerve. Hydrogen peroxide is a gentler oxidising agent that also aids haemostasis. **Thermal**: Cryotherapy with liquid nitrogen produces the largest necrotic margin — about 1-2 cm of freeze-thaw necrosis beyond the curetted wall — but it weakens the bone and carries a real fracture risk, and spillage causes skin necrosis and nerve injury. I protect the skin with warm saline irrigation and a gauze gutter, prefer modern closed-probe systems over the open pour, augment the construct, and protect weight-bearing. The PMMA polymerisation exotherm of about 60-90 degrees is itself a thermal adjuvant. **Mechanical / other**: The high-speed burr is a mechanical adjuvant and is part of extended curettage. Argon beam coagulation thermally treats the cavity surface. **Systemic (GCT-specific)**: Denosumab is a RANKL inhibitor used as a neoadjuvant for axial or unresectable GCT. It reossifies and controls disease but forms a bony rind that obscures the curettage plane, can leave viable tumour beneath it, rebounds when stopped, and does not reduce curettage recurrence — so I would not rely on it for a resectable appendicular lesion. Whatever adjuvant I use, I protect the soft tissues with a sealed field and lavage the cavity before reconstruction.
CLINICAL SCENARIOAdvanced

CLINICAL PROMPT

"You are reconstructing the cavity after extended curettage of a peri-articular giant cell tumour. You have a choice between PMMA cement and bone graft. How do you decide, and what are the trade-offs?"

PRACTICAL APPROACH
The choice between cement and graft turns on three things: the need for immediate stability, the value of an adjuvant effect, and the ease of surveillance for recurrence. **Why I usually choose cement for peri-articular GCT**: PMMA gives immediate structural stability so the patient can mobilise early; its polymerisation exotherm of about 60-90 degrees is a free thermal adjuvant that kills residual cells at the cavity wall; and crucially the sharp cement-bone interface makes radiographic surveillance straightforward — a recurrence shows as a lucent rim or new lysis at that interface, and most GCT recurrences appear within 2 years. Cement also tolerates a large defect quickly. **The downsides of cement**: it does not biologically restore bone, and against the subchondral plate it transmits heat and stiffness to the cartilage, which over years can contribute to joint degeneration. I mitigate this by laying a thin layer of subchondral cancellous graft (or leaving a small gap) between the cement and the articular surface as a buffer, and I add internal fixation if the construct is structurally weak. **When I would favour bone graft or substitute**: in children and the growing skeleton where biological restoration matters and the joint must not be insulted; in smaller benign cysts such as a simple bone cyst or chondroblastoma where surveillance is less of a concern and incorporation is desirable. The trade-off is that incorporating graft radiographically mimics recurrence and obscures surveillance, it offers no adjuvant effect, and autograft carries donor-site morbidity while substitutes risk resorption or non-incorporation. **Composite constructs**: For a large peri-articular defect I often combine cement with a plate (and sometimes screws set in the cement) to build a stable composite, with the subchondral graft buffer protecting the joint.

Curettage, Local Adjuvant & Reconstruction — Exam Day Summary

Clinical summary

Evidence Base

Giant-cell tumor of bone — defining series and radiographic grading

III
Campanacci M, Baldini N, Boriani S, Sudanese A • J Bone Joint Surg Am
Clinical Implication: Establishes the Campanacci I-III grading (cortical integrity, not malignancy) and that intralesional surgery alone carries a substantial recurrence rate — the rationale for adding a burr and adjuvant to make curettage 'extended'.
Verify on PubMed (PMID 3805057)

Giant cell tumor of bone: risk factors for recurrence

III
Klenke FM, Wenger DE, Inwards CY, Rose PS, Sim FH • Clin Orthop Relat Res
Clinical Implication: Supports intralesional curettage with PMMA as the default for most primary appendicular GCT, and shows that cement (not phenol) is the reconstruction-adjuvant that most reliably reduces recurrence in this cohort.
Verify on PubMed (PMID 20706812)

High-speed burring with and without surgical adjuvants in intralesional management of GCT — systematic review and meta-analysis

II
Algawahmed H, Turcotte R, Farrokhyar F, Ghert M • Sarcoma
Clinical Implication: Reframes the adjuvant debate: the high-speed burr (mechanical extension of the margin) is the key step, and the marginal benefit of an additional chemical/thermal adjuvant is unproven — adjuvant choice remains surgeon- and centre-dependent rather than mandatory.
Verify on PubMed (PMID 20706639)

Denosumab may increase the risk of local recurrence in GCT treated with curettage

III
Errani C, Tsukamoto S, Leone G, et al. • J Bone Joint Surg Am
Clinical Implication: Neoadjuvant denosumab does NOT reduce, and may substantially increase, recurrence after curettage by leaving viable tumour beneath a reossified rind — it should not be relied upon for resectable appendicular disease.
Verify on PubMed (PMID 29557866)

Denosumab in patients with giant-cell tumour of bone — multicentre, open-label, phase 2 study

II
Chawla S, Blay JY, Rutkowski P, et al. • Lancet Oncol
Clinical Implication: Defines the legitimate role of denosumab — neoadjuvant downstaging of unsalvageable or high-morbidity axial/pelvic GCT — while flagging ONJ, hypophosphataemia and rare malignant transformation, not routine appendicular curettage.
Verify on PubMed (PMID 31704134)

Cryosurgery in the treatment of giant cell tumors of bone — 52 consecutive cases

IV
Marcove RC, Weis LD, Vaghaiwalla MR, Pearson R, Huvos AG • Cancer
Clinical Implication: Established cryotherapy as a powerful adjuvant producing a wide necrotic margin, while defining the fracture and skin-necrosis risks that mandate construct augmentation and skin protection — principles that persist with modern closed-probe systems.
Verify on PubMed (PMID 638982)

References

  1. Campanacci M, Baldini N, Boriani S, Sudanese A (1987). Giant-cell tumor of bone. J Bone Joint Surg Am 69(1):106-14. PMID 3805057.

  2. Klenke FM, Wenger DE, Inwards CY, Rose PS, Sim FH (2011). Giant cell tumor of bone: risk factors for recurrence. Clin Orthop Relat Res 469(2):591-9. PMID 20706812.

  3. Algawahmed H, Turcotte R, Farrokhyar F, Ghert M (2010). High-speed burring with and without the use of surgical adjuvants in the intralesional management of giant cell tumor of bone: a systematic review and meta-analysis. Sarcoma 2010:586090. PMID 20706639.

  4. Chawla S, Blay JY, Rutkowski P, et al. (2019). Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study. Lancet Oncol 20(12):1719-29. PMID 31704134.

  5. Errani C, Tsukamoto S, Leone G, et al. (2018). Denosumab may increase the risk of local recurrence in patients with giant-cell tumor of bone treated with curettage. J Bone Joint Surg Am 100(6):496-504. PMID 29557866.

  6. Marcove RC, Weis LD, Vaghaiwalla MR, Pearson R, Huvos AG (1978). Cryosurgery in the treatment of giant cell tumors of bone: a report of 52 consecutive cases. Cancer 41(3):957-69. PMID 638982.